# An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

> **NCT07299890** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab and Pertuzumab Combination with Palbociclib and Exemestane

## Key facts

- **NCT ID:** NCT07299890
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299890, "An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07299890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*